{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29","upperLimit":"63.9","value":"43"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"Time to relapse or death as a result of any cause was evaluated at 2 years and the progression free survival rate was reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity.\n\ntherapeutic allogeneic lymphocytes: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (DLI)"}],"paramType":"NUMBER","populationDescription":"Patients received at least one DLI Treatment.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}